Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient
NCT06870500
Summary
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema. Psoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.
Eligibility
Inclusion Criteria: * Patients aged 18 years and above. * Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disorders affect immune system function. * Patients with liver or kidney impairment. * Patients with allergy or contraindication to methotrexate. * Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
Conditions2
Interventions1
Related trials
- A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. — Shanghai Institute Of Biological Products
- Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil — Instituto do Cancer do Estado de São Paulo
- Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL — First Affiliated Hospital of Zhejiang University
- Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients — King Faisal Specialist Hospital & Research Center
- Effect of MTX Discontinuation on Shingrix Response in RA — Konkuk University Medical Center
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL — Institute of Hematology & Blood Diseases Hospital, China
- Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis. — Ain Shams University
- Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage — Institute of Hematology & Blood Diseases Hospital, China
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06870500